公开(公告)号：WO2023025231A1

公开(公告)日：2023-03-02

申请号：PCT/CN2022/114705

申请日：2022-08-25

申请人： 丽珠医药集团股份有限公司

发明人： 李普成 ,  莫雅婷 ,  张象娜 ,  胡斯文 ,  侯雪梅 ,  江晓漫 ,  林伟珊 ,  韩智慧 ,  崔艳南 ,  成彩华

IPC分类号： A61K47/36 ,  A61K47/42 ,  A61K9/16 ,  A61K31/4439 ,  A61P1/00 ,  A61P29/00 ,  A61P1/04 ,  A61P37/08 ,  A61P1/14 ,  A61P31/04 ,  A61P7/04

摘要： 本发明涉及用于干混悬剂的干混悬颗粒，包含所述干混悬颗粒的干混悬剂，及其制备方法和用途。该干混悬颗粒包含阴离子型凝胶剂和阳离子型聚合物，其中，所述阴离子型凝胶剂与所述阳离子型聚合物的重量比为(0.5～50):1。

公开(公告)号：WO2023021109A1

公开(公告)日：2023-02-23

申请号：PCT/EP2022/073001

申请日：2022-08-17

申请人： CANTAB BIOPHARMACEUTICALS PATENTS LIMITED

发明人： WOLF-GARRAWAY, Richard ,  TUDDENHAM, Edward

IPC分类号： A61K9/12 ,  A61K9/00 ,  A61K47/10 ,  A61K47/24 ,  A61K38/37 ,  A61P7/04

摘要： The present invention relates to the use of colloidal particles for the treatment of haemophilia A in patients with antibody inhibitors or with a history of developing antibody inhibitors to Factor VIII (FVIII). The invention also relates to methods, kits and dosage forms comprising colloidal particles for treating haemophilia A in patients with antibody inhibitors or with a history of developing antibody inhibitors to Factor VIII (FVIII).

公开(公告)号：WO2023017020A1

公开(公告)日：2023-02-16

申请号：PCT/EP2022/072325

申请日：2022-08-09

申请人： GRIFOLS WORLDWIDE OPERATIONS LIMITED

发明人： GRANCHA GAMON, Salvador ,  FARO TOMAS, Maria Mercedes ,  MARTINEZ CREUS, Nuria

IPC分类号： A61K38/37 ,  A61K9/00 ,  A61K9/19 ,  A61K47/18 ,  A61P7/04

摘要： The present invention refers to a new method for producing a lyophilized pharmaceutical composition comprising human plasma-derived Factor Vlll/Von Willebrand Factor (FVIII/VWF) complex, comprising the steps of: a) providing an initial aqueous solution comprising FVIII/VWF with at least (90) III of FVIII per mg of total proteins, with a ratio of VWF/FVIII activity of at least 0.7; b) adding arginine, histidine, and human serum albumin (HAS); c) lyophilizing the FVIII/VWF solution obtained in step b); and d) reconstituting the lyophilized FVIII/VWF in water for injection thereby obtaining a therapeutic product adequate for the treatment of Hemophilia A and Von Willebrand Disease, wherein prior to administration to a patient, arginine is at a concentration between (42) and (98) mmol/L, histidine is at a concentration between (10) and (24) mmol/L, and albumin is at a concentration between (1) and (2.5) % (w/v), FVIII potency and VWF potency are equal to or higher than 200 ILI/mL, and the obtained product has a FVIII dose up to 3600 lU/vial and a VWF dose up to 5040 lll/vial.

公开(公告)号：WO2022271962A1

公开(公告)日：2022-12-29

申请号：PCT/US2022/034747

申请日：2022-06-23

申请人： BIOVERATIV THERAPEUTICS INC.

发明人： CARLAGE, Tyler ,  MAULDIN, Randall ,  TAZI, Loubna Mzaalak ,  MCCOY, Timothy R.

IPC分类号： A61K9/00 ,  A61K38/37 ,  C07K14/755 ,  A61K9/19 ,  A61K47/02 ,  A61K47/18 ,  A61K47/26 ,  A61P7/04 ,  A61K47/183 ,  A61K9/0019 ,  C07K2319/30

摘要： The present disclosure provides pharmaceutical compositions of a chimeric protein comprising a factor VIII (FVIII) polypeptide and a von Willebrand factor (VWF) polypeptide. Also disclosed are pharmaceutical kits and methods of using the disclosed pharmaceutical compositions to treat hemophilia A.

公开(公告)号：WO2022240810A1

公开(公告)日：2022-11-17

申请号：PCT/US2022/028488

申请日：2022-05-10

申请人： BIOGEN MA INC.

发明人： NISHIMURA, Naoko ,  HASUMI, Keiji ,  HONDA, Kazuo

IPC分类号： A61K31/403 ,  A61P7/04 ,  A61P9/10

摘要： To provide a safe and effective therapy and pharmaceutical composition using SMTP-7 (Compound I) or a salt thereof in cerebral infarction patients. A pharmaceutical composition for treating cerebral infarction, comprising SMTP-7 (Compound I) or a pharmacological acceptable salt thereof, which is administered at a dose of 1 to 6 mg/kg as SMTP-7 (Compound I) or a salt thereof.

公开(公告)号：WO2022234963A1

公开(公告)日：2022-11-10

申请号：PCT/KR2022/005090

申请日：2022-04-08

申请人： (주)케어젠

发明人： 정용지 ,  김은미 ,  조미희 ,  권경난

IPC分类号： C07K7/06 ,  A61K38/00 ,  A61P7/04

摘要： 본 발명은 pH 조건에 따라 겔화되는 특성이 있는 신규한 서열의 펩타이드에 관한 것으로, 상기 펩타이드는 혈액의 응고를 유도할 수 있는바 상기 펩타이드를 포함하는 조성물은 지혈을 유도하기 위한 용도로 유용하게 이용될 수 있다.

公开(公告)号：WO2022224249A1

公开(公告)日：2022-10-27

申请号：PCT/IL2022/050403

申请日：2022-04-18

申请人： RAMBAM MED-TECH LTD.

发明人： NADIR, Yona

IPC分类号： A61K38/04 ,  A61K38/10 ,  A61K38/47 ,  A61P7/04 ,  C07K7/00

摘要： There is provided procoagulant peptides, and use of same, such as in treatment of hemostasis-related diseases or disorders, and/or wound healing.

公开(公告)号：WO2022125490A1

公开(公告)日：2022-06-16

申请号：PCT/US2021/062113

申请日：2021-12-07

申请人： ALNYLAM PHARMACEUTICALS, INC. [US]/[US]

发明人： KEATING, Mark ,  ZUBER, Jeffrey

IPC分类号： C12N15/113 ,  A61K31/713 ,  A61P7/04

摘要： The present invention relates to RNAi agents, e.g., dsRNA agents, targeting the Coagulation Factor X (F10) gene. The invention also relates to methods of using such RNAi agents to inhibit expression of an F10 gene and to methods of treating or preventing an FlO-associated disease, e.g., a disorder associated with thrombosis, in a subject.

公开(公告)号：WO2022018256A1

公开(公告)日：2022-01-27

申请号：PCT/EP2021/070656

申请日：2021-07-23

申请人： UNIVERSITÉ GRENOBLE ALPES ,  CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE ,  CENTRE HOSPITALIER UNIVERSITAIRE GRENOBLE ALPES ,  INSTITUT POLYTECHNIQUE DE GRENOBLE

发明人： THOMAS, Aline ,  DAGHER, Marie-Claire ,  JOURDAN, Muriel ,  NAVARRO, Romain ,  POLACK, Benoît ,  MARLU, Raphael ,  SEYVE, Landry ,  ZELLI, Renaud

IPC分类号： A61K31/015 ,  A61K31/166 ,  A61K31/185 ,  A61K31/192 ,  A61K31/40 ,  A61K31/403 ,  A61K31/47 ,  A61P7/04

摘要： L'invention concerne un composé de formule générale (III'), ou l'un de ses sels pharmaceutiquement acceptables, pour son utilisation pour le traitement de l'hémophilie chez un sujet, en particulier pour la restauration de la coagulation dans le plasma d'un sujet atteint d'hémophilie, ce composé étant avantageusement administrable par voie orale.

公开(公告)号：WO2022013604A1

公开(公告)日：2022-01-20

申请号：PCT/IB2020/056706

申请日：2020-07-16

申请人： NOVARTIS AG

发明人： END, Peter ,  BALTCHEVA, Irina ,  MILOJEVIC, Julie Marie-Pomme Gabrielle

IPC分类号： A61K31/4439 ,  A61P7/04

摘要： Described herein are methods of treating paroxysmal nocturnal hemoglobinuria (PNH) with the Factor B inhibitor LNP023 or a pharmaceutically acceptable salt thereof, e.g. LNP023 hydrochloride.